241 related articles for article (PubMed ID: 33980212)
1. Naturalistic exploratory study of the associations of substance use on ADHD outcomes and function.
MacDonald B; Sadek J
BMC Psychiatry; 2021 May; 21(1):251. PubMed ID: 33980212
[TBL] [Abstract][Full Text] [Related]
2. The Utility of the CPT in the Diagnosis of ADHD in Individuals with Substance Abuse: A Systematic Review.
Slobodin O
Eur Addict Res; 2020; 26(4-5):283-294. PubMed ID: 32535592
[TBL] [Abstract][Full Text] [Related]
3. Differential Diagnosis in Patients with Substance Use Disorder and/or Attention-Deficit/Hyperactivity Disorder Using Continuous Performance Test.
Slobodin O; Blankers M; Kapitány-Fövény M; Kaye S; Berger I; Johnson B; Demetrovics Z; van den Brink W; van de Glind G
Eur Addict Res; 2020; 26(3):151-162. PubMed ID: 32074617
[TBL] [Abstract][Full Text] [Related]
4. The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study.
Brynte C; Aeschlimann M; Barta C; Begeman AHA; Bäcker A; Crunelle CL; Daigre C; De Fuentes-Merillas L; Demetrovics Z; Dom G; López LG; Icick R; Johnson B; Joostens P; Kapitány-Fövény M; Karsinti E; Kiefer F; Konstenius M; Levin FR; Luderer M; Markus W; Matthys F; Moggi F; Palma-Alvarez RF; Paraskevopoulou M; Ramos-Quiroga JA; Schellekens A; Soravia LM; Therribout N; Thomas A; van de Glind G; van Kernebeek MW; Vollstädt-Klein S; Vorspan F; van den Brink W; Franck J
BMC Psychiatry; 2022 Sep; 22(1):625. PubMed ID: 36151539
[TBL] [Abstract][Full Text] [Related]
5. Genetic liability to ADHD and substance use disorders in individuals with ADHD.
Wimberley T; Agerbo E; Horsdal HT; Ottosen C; Brikell I; Als TD; Demontis D; Børglum AD; Nordentoft M; Mors O; Werge T; Hougaard D; Bybjerg-Grauholm J; Hansen MB; Mortensen PB; Thapar A; Riglin L; Langley K; Dalsgaard S
Addiction; 2020 Jul; 115(7):1368-1377. PubMed ID: 31803957
[TBL] [Abstract][Full Text] [Related]
6. The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future Activities.
Van de Glind G; Brynte C; Skutle A; Kaye S; Konstenius M; Levin F; Mathys F; Demetrovics Z; Moggi F; Ramos-Quiroga JA; Schellekens A; Crunelle C; Dom G; van den Brink W; Franck J
Eur Addict Res; 2020; 26(4-5):173-178. PubMed ID: 32599579
[TBL] [Abstract][Full Text] [Related]
7. Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills.
Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
BMC Psychiatry; 2013 Dec; 13():336. PubMed ID: 24330331
[TBL] [Abstract][Full Text] [Related]
8. Adult attention-deficit/hyperactivity disorder and its association with substance use and substance use disorders in young men.
Estévez N; Dey M; Eich-Höchli D; Foster S; Gmel G; Mohler-Kuo M
Epidemiol Psychiatr Sci; 2016 Jun; 25(3):255-66. PubMed ID: 25989844
[TBL] [Abstract][Full Text] [Related]
9. Prediction of drop-out and outcome in integrated cognitive behavioral therapy for ADHD and SUD: Results from a randomized clinical trial.
van Emmerik-van Oortmerssen K; Blankers M; Vedel E; Kramer F; Goudriaan AE; van den Brink W; Schoevers RA
Addict Behav; 2020 Apr; 103():106228. PubMed ID: 31838443
[TBL] [Abstract][Full Text] [Related]
10. Genetic overlap and causality between substance use disorder and attention-deficit and hyperactivity disorder.
Vilar-Ribó L; Sánchez-Mora C; Rovira P; Richarte V; Corrales M; Fadeuilhe C; Arribas L; Casas M; Ramos-Quiroga JA; Ribasés M; Soler Artigas M
Am J Med Genet B Neuropsychiatr Genet; 2021 Apr; 186(3):140-150. PubMed ID: 33244849
[TBL] [Abstract][Full Text] [Related]
11. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
[TBL] [Abstract][Full Text] [Related]
12. Effect of Past Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder on Substance Use Disorder.
Coetzee C; Schellekens AFA; Truter I; Meyer A
Eur Addict Res; 2023; 29(1):9-18. PubMed ID: 36349763
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-Analysis.
Rohner H; Gaspar N; Philipsen A; Schulze M
Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674031
[TBL] [Abstract][Full Text] [Related]
14. Gender Differences in Associations Between Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
Ottosen C; Petersen L; Larsen JT; Dalsgaard S
J Am Acad Child Adolesc Psychiatry; 2016 Mar; 55(3):227-34.e4. PubMed ID: 26903256
[TBL] [Abstract][Full Text] [Related]
15. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study.
van Emmerik-van Oortmerssen K; van de Glind G; Koeter MW; Allsop S; Auriacombe M; Barta C; Bu ET; Burren Y; Carpentier PJ; Carruthers S; Casas M; Demetrovics Z; Dom G; Faraone SV; Fatseas M; Franck J; Johnson B; Kapitány-Fövény M; Kaye S; Konstenius M; Levin FR; Moggi F; Møller M; Ramos-Quiroga JA; Schillinger A; Skutle A; Verspreet S; ; van den Brink W; Schoevers RA
Addiction; 2014 Feb; 109(2):262-72. PubMed ID: 24118292
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis.
van Emmerik-van Oortmerssen K; van de Glind G; van den Brink W; Smit F; Crunelle CL; Swets M; Schoevers RA
Drug Alcohol Depend; 2012 Apr; 122(1-2):11-9. PubMed ID: 22209385
[TBL] [Abstract][Full Text] [Related]
17. Substance use disorder and ADHD: is ADHD a particularly "specific" risk factor?
Kousha M; Shahrivar Z; Alaghband-Rad J
J Atten Disord; 2012 May; 16(4):325-32. PubMed ID: 22127397
[TBL] [Abstract][Full Text] [Related]
18. Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders.
Icick R; Moggi F; Slobodin O; Dom G; Mathys F; van den Brink W; Levin FR; Blankers M; Kaye S; Demetrovics Z; van de Glind G; Velez-Pastrana MC; Schellekens ASA;
Eur Addict Res; 2020; 26(4-5):201-210. PubMed ID: 32570249
[TBL] [Abstract][Full Text] [Related]
19. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.
Molina BS; Hinshaw SP; Eugene Arnold L; Swanson JM; Pelham WE; Hechtman L; Hoza B; Epstein JN; Wigal T; Abikoff HB; Greenhill LL; Jensen PS; Wells KC; Vitiello B; Gibbons RD; Howard A; Houck PR; Hur K; Lu B; Marcus S;
J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):250-63. PubMed ID: 23452682
[TBL] [Abstract][Full Text] [Related]
20. Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatment-seeking adults.
Young JT; Carruthers S; Kaye S; Allsop S; Gilsenan J; Degenhardt L; van de Glind G; van den Brink W; Preen D
Drug Alcohol Rev; 2015 Nov; 34(6):683-93. PubMed ID: 25790353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
